Robenacoxib (Onsior)

Robenacoxib, marketed under the brand name Onsior, is a highly selective cyclooxygenase-2 (COX-2) inhibiting nonsteroidal anti-inflammatory drug developed specifically for veterinary use in dogs and cats. Among the available veterinary NSAIDs, robenacoxib demonstrates one of the highest degrees of selectivity for COX-2 over COX-1, a characteristic that was designed to provide effective pain relief and anti-inflammatory action while minimizing effects on the protective functions mediated by COX-1, such as gastrointestinal mucosal integrity and platelet function. In dogs, Onsior is FDA-approved for short-term use, specifically for the control of postoperative pain and inflammation associated with soft tissue surgery. This focused approval distinguishes robenacoxib from other canine NSAIDs that are approved for longer-term management of chronic conditions like osteoarthritis.

The mechanism of action of robenacoxib centers on its potent and selective inhibition of the COX-2 enzyme. When tissue damage occurs, such as during surgical procedures, the COX-2 enzyme is rapidly induced and produces prostaglandins that mediate inflammation, pain, and fever. By selectively blocking COX-2 while having minimal effect on COX-1, robenacoxib reduces the production of inflammatory prostaglandins responsible for postoperative pain and swelling without substantially affecting the prostaglandins that protect the stomach lining and support normal blood clotting. Laboratory studies have demonstrated that robenacoxib achieves therapeutic concentrations in inflamed tissues faster than in plasma, suggesting targeted delivery to sites where the drug is most needed.

Onsior for dogs is available in multiple formulations to accommodate various clinical scenarios. Tablets come in four strengths: 5 mg, 10 mg, 20 mg, and 40 mg, allowing for appropriate dosing across the range of dog sizes. An injectable formulation is also available for use in clinical settings, providing flexibility for perioperative pain management. The tablets are designed for once-daily oral administration and should be given at least 30 minutes before feeding or at least two hours after feeding for optimal absorption. Unlike some other veterinary NSAIDs that feature highly palatable flavoring, Onsior tablets are not specifically formulated to be treat-like, which may require more effort from owners during administration but also reduces the risk of dogs seeking out the medication.

Veterinary supervision is essential when using robenacoxib, as with all prescription NSAIDs. The specific approval for short-term postoperative use in dogs means that treatment duration is limited, and the medication should not be used continuously for extended periods without explicit veterinary guidance. Pre-surgical patient assessment helps identify dogs that may be at increased risk for adverse effects, allowing for appropriate monitoring or selection of alternative pain management strategies. Following the prescribed dosing schedule and duration is particularly important with robenacoxib, and owners should not extend treatment beyond the veterinarian's recommendations without consultation. The high COX-2 selectivity of robenacoxib offers theoretical safety advantages, but all NSAIDs require appropriate patient selection and monitoring to ensure safe use.

The FDA-approved indication for robenacoxib tablets in dogs is the control of postoperative pain and inflammation associated with soft tissue surgery for a maximum of three days. This specific and limited approval reflects the clinical trials that supported the drug's registration, which focused on acute pain management rather than chronic conditions. Soft tissue surgeries encompass a wide range of procedures, including spay (ovariohysterectomy), neuter (castration), mass removals, wound repairs, abdominal surgeries, and other non-orthopedic surgical interventions. The controlled pain and inflammation during the critical immediate postoperative period promotes patient comfort, facilitates recovery, and may improve surgical outcomes by allowing for earlier mobility and return to normal activities.

Robenacoxib's injectable formulation provides additional flexibility in perioperative pain management protocols. The injection can be administered before surgery to establish anti-inflammatory effects before tissue trauma occurs (preemptive analgesia) or immediately after surgery when oral medication may not be feasible. This injectable-to-oral transition allows veterinarians to provide seamless pain control throughout the perioperative period, starting with an injection in the clinic and continuing with tablets sent home for owner administration during the recovery days. The combination approach ensures continuous pain management without gaps that could result in unnecessary patient discomfort.

While robenacoxib's approved use in dogs is limited to short-term postoperative pain management, the medication may occasionally be prescribed off-label for other acute painful or inflammatory conditions. Veterinarians might consider robenacoxib for acute musculoskeletal injuries, dental procedures, or other situations requiring short-term NSAID therapy. However, any use beyond the approved indication requires careful veterinary judgment about the appropriateness for the individual patient and situation. The three-day maximum duration specified in the label should generally be respected unless the veterinarian determines that extended use is warranted and implements appropriate monitoring.

The selection of robenacoxib over other available NSAIDs for postoperative pain management depends on multiple factors that veterinarians evaluate for each patient. Its high COX-2 selectivity may make it an attractive choice for patients where gastrointestinal safety is a particular concern, though all NSAIDs require caution in this regard. The availability of multiple tablet sizes allows for appropriate dosing across a wide range of dog sizes without the need for tablet splitting. For practices that prefer to use the same NSAID in both dogs and cats, robenacoxib offers the advantage of being approved for both species, simplifying inventory and protocols. The specific approval for soft tissue surgery aligns well with common procedures such as spays and neuters that constitute a large portion of veterinary surgical caseloads.

It is important for dog owners to understand that robenacoxib is not approved for long-term management of chronic conditions such as osteoarthritis in dogs, unlike some other veterinary NSAIDs. While dogs with osteoarthritis might occasionally receive robenacoxib for short periods, the approved chronic pain management options include other NSAIDs such as carprofen, meloxicam, firocoxib, and grapiprant that have been specifically studied and approved for extended use. Using robenacoxib continuously for osteoarthritis or other chronic conditions would represent off-label use requiring careful veterinary oversight, and alternative medications approved for such purposes are generally more appropriate choices.

The dosing of robenacoxib in dogs must be determined by a veterinarian based on the individual patient's accurate body weight and specific surgical procedure. The approved dose for dogs is 2 mg per kilogram of body weight (approximately 0.9 mg per pound) administered once daily for a maximum of three consecutive days. This dosing regimen applies to the oral tablet formulation used for postoperative pain management at home following discharge from the veterinary facility. Accurate weight measurement is essential, as improper dosing can lead to inadequate pain control if underdosed or increased risk of adverse effects if overdosed. The veterinarian selects the appropriate tablet strength or combination to achieve the target dose as closely as possible.

Onsior tablets are available in four strengths specifically to accommodate the weight-based dosing requirements across the range of dog sizes: 5 mg, 10 mg, 20 mg, and 40 mg. Small dogs may require the 5 mg or 10 mg tablets, medium dogs typically use the 10 mg or 20 mg tablets, and large to giant breeds may need the 40 mg tablets or combinations thereof. The tablets are scored to allow for division when necessary to achieve more precise dosing, though breaking tablets should be done according to the manufacturer's guidance. Dogs must weigh at least 5.5 pounds (2.5 kg) to receive robenacoxib therapy, as safety and efficacy have not been established in smaller patients.

The treatment duration for robenacoxib in dogs is specifically limited to a maximum of three days according to the FDA-approved labeling. This short-term treatment period aligns with the approved indication for postoperative pain management, during which acute inflammation is typically most pronounced. The first dose may be administered on the day of surgery, often following an initial injectable dose given in the clinic, with subsequent doses given once daily for up to two additional days. Extending treatment beyond three days requires explicit veterinary instruction and represents off-label use that should be approached with appropriate caution and monitoring.

Unlike some other veterinary NSAIDs that can be given with or without food, robenacoxib tablets should be administered on an empty stomach for optimal absorption. The manufacturer recommends giving the medication at least 30 minutes before feeding or at least two hours after a meal. This requirement stems from studies showing that food can reduce the absorption of robenacoxib, potentially affecting its efficacy. Since the tablets are not flavored to be palatable like treats, they may need to be administered directly into the mouth or with a minimal amount of food if the dog will not accept them otherwise, understanding that this may slightly reduce absorption. Consistent timing of doses helps maintain appropriate drug levels.

If a dose of robenacoxib is missed, it should be given as soon as remembered, provided it is not close to the time for the next scheduled dose. Given the short three-day treatment course, missing doses can significantly impact pain control during the recovery period, so establishing a reliable dosing routine from the outset is important. Owners should never double up on doses to compensate for missed medication, as this increases the risk of adverse effects. If multiple doses are missed or if there are concerns about adequate pain control, the veterinarian should be contacted for guidance. Since robenacoxib therapy in dogs is limited to three days, questions about extending treatment require veterinary consultation.

Completing the full prescribed course of robenacoxib is important for optimal postoperative comfort, even if the dog appears to be feeling well before all doses have been given. Underlying inflammation may persist after surgery even when outward signs of discomfort have diminished, and discontinuing anti-inflammatory therapy prematurely could allow pain to return. However, owners should also remain alert for any signs of adverse effects throughout the treatment period and should contact their veterinarian if concerns arise rather than automatically completing all doses if problems develop. Follow-up communication with the veterinary clinic regarding the dog's recovery ensures appropriate ongoing care.

Robenacoxib is generally well-tolerated by most dogs when used according to the approved short-term dosing regimen under veterinary supervision. The high COX-2 selectivity of robenacoxib was specifically designed to reduce the risk of certain adverse effects associated with less selective NSAIDs, particularly gastrointestinal complications. Clinical trials in dogs demonstrated a favorable safety profile during the approved three-day treatment period. However, as with all NSAIDs, robenacoxib carries the potential for adverse reactions, and owners should be aware of possible side effects to monitor for during treatment and know when to seek veterinary attention.

The most commonly observed side effects of robenacoxib in dogs involve the gastrointestinal system, including vomiting, diarrhea, soft stools, and decreased appetite. In clinical field studies, these effects occurred in a small percentage of treated dogs and were generally mild and self-limiting. The high COX-2 selectivity of robenacoxib means that theoretical gastrointestinal risk may be lower than with some other NSAIDs, as COX-1-derived prostaglandins that help protect the stomach lining are relatively preserved. Nevertheless, any persistent gastrointestinal upset, particularly if severe or worsening, warrants veterinary attention to determine whether the medication should be continued or if additional supportive care is needed.

More serious gastrointestinal complications, though uncommon, can include gastric ulceration and gastrointestinal bleeding. These events are possible with any NSAID regardless of COX selectivity, though the risk may be reduced with highly COX-2 selective agents like robenacoxib. Signs of gastrointestinal bleeding include bloody or dark tarry stools, vomiting blood or coffee-ground-like material, abdominal pain, pale gums, weakness, or collapse. Any of these symptoms require immediate veterinary attention, as gastrointestinal ulceration can progress rapidly to serious complications. Dogs with pre-existing gastrointestinal conditions or those receiving concurrent medications that affect the digestive tract may be at elevated risk.

Renal and hepatic effects are potential concerns with NSAID therapy, though the short duration of approved robenacoxib use in dogs limits prolonged exposure. NSAIDs can affect kidney function by reducing prostaglandin-mediated renal blood flow, which is particularly concerning in dogs that are dehydrated, have pre-existing kidney disease, or are under anesthetic stress. Signs of kidney problems may include changes in urination patterns, increased thirst, decreased appetite, or lethargy. Liver-related adverse effects, while uncommon, might manifest as jaundice (yellowing of the gums or eyes), vomiting, loss of appetite, or behavioral changes. Pre-surgical blood work helps identify dogs with compromised organ function who may be at higher risk.

Rare adverse effects associated with robenacoxib may include allergic reactions, skin reactions, or idiosyncratic responses. Signs of allergic reaction include facial swelling, hives, difficulty breathing, or collapse and require immediate emergency care. Any unexpected or concerning symptoms during robenacoxib treatment should prompt discontinuation of the medication and consultation with the veterinarian. Given the short three-day treatment course, long-term adverse effects are generally not a concern with approved use, though dogs receiving extended off-label treatment would require more vigilant monitoring. The overall benefit-risk assessment for robenacoxib in postoperative pain management is favorable when the medication is used appropriately in carefully selected patients.

Robenacoxib should not be administered to dogs with known hypersensitivity or allergy to robenacoxib or other NSAIDs. Dogs that have experienced adverse reactions to any NSAID in the past, including symptoms such as facial swelling, hives, difficulty breathing, gastrointestinal bleeding, or severe digestive upset, should not receive robenacoxib without careful veterinary consideration of the risks and benefits. Cross-reactivity between different NSAIDs can occur, so a history of intolerance to one NSAID may predict problems with others in the class. Complete disclosure of any previous adverse drug reactions to the veterinarian ensures informed decision-making about appropriate pain management options.

Dogs with pre-existing kidney disease or impaired renal function represent a significant contraindicated population for robenacoxib therapy. NSAIDs can compromise kidney function through their effects on prostaglandin-mediated renal blood flow, potentially precipitating acute kidney injury or worsening existing chronic kidney disease. This concern is particularly relevant in the surgical setting where anesthesia, fluid shifts, and potential hypotension may already stress the kidneys. Dogs that are dehydrated, hypovolemic, or in shock should not receive robenacoxib until their fluid status has been corrected and stabilized. Pre-surgical blood work to evaluate kidney function helps identify at-risk patients who may require alternative analgesic strategies.

Hepatic disease constitutes another contraindication for robenacoxib use in dogs. The liver is responsible for metabolizing robenacoxib, and dogs with hepatic impairment may not process the drug normally, potentially leading to accumulation and increased toxicity risk. Additionally, NSAIDs can occasionally cause hepatotoxicity even in dogs with previously normal liver function. Dogs with active liver disease, significantly elevated liver enzymes, or clinical signs of hepatic dysfunction should not receive robenacoxib. Pre-treatment liver function testing helps identify dogs that may be at elevated risk for hepatic adverse effects.

Robenacoxib should not be used in dogs weighing less than 5.5 pounds (2.5 kg), as safety and efficacy have not been established in very small dogs. Dogs younger than four months of age should not receive robenacoxib due to the lack of safety data in very young animals with still-developing organ systems. Pregnant and nursing dogs should avoid robenacoxib, as effects on reproduction, fetal development, and nursing puppies have not been adequately characterized. Dogs with active gastrointestinal ulceration or bleeding should not receive any NSAID, as these medications can exacerbate such conditions. Bleeding disorders or concurrent anticoagulant therapy require careful evaluation before NSAID use. Complete and accurate medical history disclosure to the veterinarian ensures that contraindicated patients are identified and safer alternatives are selected.

Providing the veterinarian with a complete list of all medications, supplements, and products your dog receives is essential before robenacoxib therapy begins. Drug interactions can alter medication efficacy, affect drug metabolism, or increase the risk of serious adverse effects. In the perioperative setting, dogs may receive multiple medications for anesthesia, pain control, infection prevention, and other purposes, making interaction assessment particularly important. Even products that seem benign can potentially interact with prescription medications in clinically meaningful ways, and the veterinary team needs comprehensive information to ensure safe care.

The concurrent use of robenacoxib with other NSAIDs is contraindicated due to the substantially increased risk of gastrointestinal ulceration, bleeding, and kidney damage when these medications are combined. This prohibition applies to all other prescription NSAIDs, including carprofen, meloxicam, firocoxib, and deracoxib, as well as human over-the-counter NSAIDs such as ibuprofen, naproxen, and aspirin. Even low-dose aspirin should not be combined with robenacoxib. If a dog has been receiving another NSAID, an appropriate washout period should be observed before starting robenacoxib. The duration of this washout period depends on the half-life of the previous NSAID and should be determined by the veterinarian, typically ranging from several days to a week.

Corticosteroids and robenacoxib should not be used concurrently due to the dramatically increased risk of gastrointestinal adverse effects when these drug classes are combined. Both NSAIDs and corticosteroids can independently cause gastric ulceration, and their concurrent use synergistically amplifies this risk. If a dog has been receiving corticosteroid therapy, a washout period is necessary before initiating robenacoxib treatment. The required washout duration depends on the specific corticosteroid, dose, and treatment length, and should be determined by the prescribing veterinarian. In rare cases where both drug classes are considered medically necessary, gastroprotective therapy and intensive monitoring would be essential.

Robenacoxib may interact with other medications commonly used in veterinary medicine and in perioperative protocols. Potential interactions exist with anticoagulant medications, which could increase bleeding risk. ACE inhibitors, angiotensin receptor blockers, and diuretics used for cardiac conditions may have reduced effectiveness when combined with NSAIDs, and concurrent use may increase the risk of kidney problems. Nephrotoxic drugs such as aminoglycoside antibiotics pose heightened kidney risk when combined with NSAIDs. The anesthetic and analgesic agents used during surgery may interact with robenacoxib, and veterinary anesthetists consider these interactions when designing perioperative protocols.

Supplements and over-the-counter products should also be disclosed before robenacoxib therapy. Fish oil supplements have mild anticoagulant properties that may be additive with NSAID effects on platelet function. While joint supplements like glucosamine and chondroitin do not typically interact adversely with NSAIDs, disclosure ensures complete information is available. Herbal supplements with anti-inflammatory or blood-thinning properties warrant particular attention. Any changes to the dog's medication or supplement regimen during or after robenacoxib therapy should be communicated to the veterinarian.

General precautions for robenacoxib use begin with appropriate patient selection and accurate dosing based on precise body weight measurement. Pre-surgical assessment, including blood work to evaluate liver and kidney function, helps identify dogs that may be at increased risk for adverse effects and allows for alternative pain management strategies when indicated. Dogs should be adequately hydrated before surgery and NSAID administration to reduce the risk of kidney-related complications. The medication should only be used in dogs for which it has been specifically prescribed, and owners should not share medication between pets or use leftover robenacoxib for future surgical procedures without veterinary consultation.

While robenacoxib does not carry the same specific concerns regarding the MDR1 (ABCB1) gene mutation that affects metabolism of certain other medications, general awareness of breed-related drug sensitivities remains important for comprehensive patient care. Herding breeds such as Collies, Australian Shepherds, Shetland Sheepdogs, Border Collies, and related breeds and mixes have higher prevalence of the MDR1 mutation. Although this mutation primarily affects different drug classes, owners of these breeds should inform their veterinarian of their dog's breed background. Any unusual sensitivity or adverse reaction to robenacoxib or any medication in these breeds should be reported and carefully evaluated.

The specific labeling for robenacoxib includes important warnings that owners and veterinarians should heed. The medication is approved only for short-term use, with a maximum treatment duration of three days in dogs. Extending treatment beyond this period represents off-label use requiring veterinary judgment and appropriate monitoring. The tablets should be administered on an empty stomach as directed to ensure optimal absorption. Dogs must weigh at least 5.5 pounds and be at least four months of age to receive robenacoxib. These requirements reflect the populations in which safety and efficacy have been established through clinical trials.

Monitoring during the short treatment course includes owner observation for any changes in appetite, water consumption, urination, stool quality, energy level, or behavior. Signs of gastrointestinal distress such as vomiting, diarrhea, or refusal to eat should be noted. Given the postoperative context, owners should also monitor the surgical site for appropriate healing and report any concerns about excessive swelling, discharge, or other abnormalities. While extensive laboratory monitoring is not typically necessary for a three-day treatment course in otherwise healthy dogs, any dogs identified as higher risk may warrant closer veterinary follow-up.

Special considerations apply to certain patient populations receiving robenacoxib. Dogs with concurrent health conditions, particularly cardiac, hepatic, or renal disease, require thorough benefit-risk assessment. Geriatric dogs often have age-related decline in organ function that may increase susceptibility to NSAID adverse effects. Dogs receiving other medications need careful evaluation for potential interactions. Following soft tissue surgery, dogs should have appropriate activity restriction during recovery regardless of pain medication efficacy, as the analgesic effects of robenacoxib could mask discomfort that would otherwise naturally limit activity. Postoperative care instructions from the veterinary team should be followed carefully.

Proper storage of robenacoxib tablets maintains medication efficacy and safety throughout the short treatment course. Onsior tablets should be stored at controlled room temperature, typically below 86 degrees Fahrenheit (30 degrees Celsius). The medication should be kept in its original packaging to protect from light and moisture until ready for administration. Storage areas should be dry and away from heat sources, direct sunlight, or areas subject to significant temperature fluctuation. Bathrooms, kitchens near stoves, and vehicles are generally unsuitable storage locations due to humidity and temperature extremes.

Secure storage prevents accidental ingestion by household pets or children. Unlike some veterinary NSAIDs that feature highly palatable flavoring, robenacoxib tablets are not formulated to taste like treats, which somewhat reduces the risk of dogs actively seeking out the medication. However, any medication can be harmful if consumed in excess, and dogs are often indiscriminate about what they will eat. Medications should be stored in locations completely inaccessible to pets and children, such as high cabinets, locked containers, or medicine cabinets with secure closures. The blister packaging provides individual dose protection but should still be stored securely. Never leave medications on counters, tables, or other accessible surfaces.

Proper disposal of any unused robenacoxib protects household members and the environment. Given the short three-day treatment course, there typically should not be significant leftover medication if the appropriate quantity was dispensed. However, if doses remain after treatment is complete, they should be disposed of properly rather than saved for potential future use. Drug take-back programs offered by pharmacies, veterinary clinics, and community organizations provide the safest disposal method. If take-back programs are unavailable, the FDA recommends mixing medications with an undesirable substance such as coffee grounds or cat litter, sealing the mixture in a container, and disposing of it in household trash. Remove personal information from packaging before disposal. Medications should not be flushed down toilets or poured down drains unless specifically directed, due to environmental concerns about pharmaceutical contamination of water supplies.

Robenacoxib is generally well-tolerated across the diverse range of dog breeds when used according to approved labeling and veterinary guidance. The considerable variation in canine body size primarily affects dosing calculations, with the multiple tablet strengths (5 mg, 10 mg, 20 mg, and 40 mg) designed to accommodate appropriate dosing across the size spectrum. Veterinarians consider breed-related factors alongside individual patient characteristics when prescribing robenacoxib for postoperative pain management. Owner awareness of their dog's breed background, including any mixed breed heritage, supports comprehensive veterinary care.

Certain breed-specific health predispositions warrant consideration in the context of perioperative NSAID use. Breeds with increased prevalence of kidney disease should have appropriate pre-surgical screening to identify renal compromise that might increase risk from NSAID therapy. Breeds prone to liver conditions benefit from hepatic function assessment before treatment. Some breeds have known predispositions to bleeding disorders that could affect decisions about medications influencing platelet function. Breeds with gastrointestinal sensitivities may be at elevated risk for digestive adverse effects, though robenacoxib's high COX-2 selectivity may offer some advantage in this regard. Brachycephalic breeds (flat-faced dogs) often face increased anesthetic risk and may have multiple concurrent health considerations affecting perioperative medication choices.

Size considerations influence robenacoxib therapy across the breed spectrum, though the short treatment duration limits cumulative concerns. Very small dogs approaching the minimum weight threshold of 5.5 pounds require precise dosing and may benefit from the 5 mg tablets. Giant breeds such as Great Danes, Mastiffs, and Irish Wolfhounds may need multiple tablets to achieve appropriate dosing. The postoperative pain management needs following soft tissue surgery are generally similar across breeds, with the procedure type and extent being more relevant factors than breed itself for determining analgesic requirements.

Age considerations intersect with breed factors in perioperative pain management decisions. Large and giant breed dogs are often considered senior at younger chronological ages than small breeds, potentially affecting their risk profile for NSAID therapy. Conversely, the four-month minimum age requirement applies across all breeds. Geriatric dogs of any breed may have age-related decline in organ function that warrants more cautious NSAID use and potentially enhanced monitoring. Pediatric patients just meeting the age requirement should be assessed carefully to ensure appropriate development before NSAID therapy. Regardless of breed or age, individual patient assessment remains the foundation for safe and effective perioperative pain management with robenacoxib.

Several other veterinary-approved NSAIDs can serve as alternatives to robenacoxib for perioperative and short-term pain management in dogs. Meloxicam (Metacam) is widely used and offers both injectable and oral formulations for perioperative pain control. Carprofen (Rimadyl) has a long track record and injectable options for hospital use followed by oral tablets for home administration. Firocoxib (Previcox) and deracoxib (Deramaxx) are COX-2 selective options available in oral formulations. The choice among these alternatives depends on individual patient factors, veterinarian preference, formulation requirements, and cost considerations. Unlike robenacoxib, several of these alternatives are also approved for chronic pain management, offering flexibility if extended therapy becomes necessary.

For postoperative pain management, multimodal analgesia combining medications with different mechanisms often provides superior comfort compared to any single agent. Opioid analgesics such as buprenorphine, hydromorphone, or methadone are commonly used in the perioperative period for their potent pain-relieving effects. Local anesthetics administered during surgery provide targeted pain control at the surgical site. Alpha-2 agonists like dexmedetomidine contribute both sedation and analgesia in perioperative protocols. NMDA receptor antagonists like ketamine at sub-anesthetic doses may be incorporated for certain procedures. Veterinary anesthetists design multimodal protocols tailored to the specific procedure and individual patient needs.

Complementary approaches support medication-based pain management during surgical recovery. Appropriate rest and restricted activity prevent strain on surgical sites and promote healing. Comfortable bedding supports recuperating patients. Environmental modifications may be needed to prevent jumping or stair climbing during recovery. Cold therapy (ice packs properly wrapped) can reduce swelling in the immediate postoperative period for some surgeries. Nutritional support maintains strength during healing. Physical rehabilitation techniques may be introduced as appropriate during later recovery stages. Follow-up veterinary visits allow assessment of healing progress and pain levels. Any concerns about inadequate pain control or complications should prompt communication with the veterinary team. The goal of perioperative pain management is smooth, comfortable recovery that supports optimal surgical outcomes.